首页 > 用药指导 > 文章详情

Baricitinib(艾乐明)的药物禁忌说明

发布时间:2023-12-10 15:33:27 阅读:1557 来源:问药网
分享至

分享到微信朋友圈

×

打开微信,点击底部的“发现”,

使用“扫一扫”即可将网页分享至朋友圈。

巴瑞替尼片

巴瑞替尼片 生产厂家:孟加拉DIL耀品国际制药公司 功能主治:对一种或多种抗风湿药物缓解不足或不耐受的中度至重 用法用量:用法用量  1、类风湿性关节炎  OLUMIANT的推荐剂量为每日1次口服2mg,餐前餐后都可。  OLUMIANT可以单独使用,也可以与甲氨蝶呤或其他非生物dmard联合使用。  2、COVID-19(新冠病毒)  成人OLUMIANT的推荐剂量为每日一次口服4mg,餐前餐后都可,持续14天或直到出院,以先发生者为准。  3、斑秃  OLUMIANT的推荐剂量是2mg,每天一次口服,餐前餐后都可。  如果对治疗的反应不充分,增加到每天一次4mg。  对于几乎完全或完全的头皮脱发,睫毛或眉毛有或没有大量脱发的患者,考虑每天一次4mg治疗,伴餐前餐后都可。  一旦患者对4mg的治疗产生了充分的反应,将剂量减少到2mg,每天一次。  对于无法吞下整片药片的患者,可以考虑另一种给药方式:  1、口服分散  2、胃造口管(G管)  3、鼻胃管(NG管)或口胃管(OG管)
查看详情

Baricitinib(艾乐明)的药物禁忌说明,Baricitinib(Baricitinib)禁忌为:1、对巴瑞替尼或药物中的任何成分过敏的患者禁用;2、存在严重活动性感染的患者禁用;3、具有严重肝功能损害的患者禁用;4、孕妇患者禁用;5、哺乳期妇女患者禁用。

Baricitinib (brand name: Olumiant) is a medication used for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. However, like any medication, Baricitinib has certain contraindications and precautions that need to be considered before its use. In this article, we will explore the contraindications associated with Baricitinib and provide important information to ensure its safe and effective use.

1. Introduction

2. Contraindications of Baricitinib

3. Precautions and Warnings

4. Conclusion

1. Contraindications of Baricitinib

Baricitinib should not be taken if any of the following conditions apply:

1.1 Known hypersensitivity: Individuals with a known hypersensitivity to Baricitinib or any of its components should not use this medication. Allergic reactions can range from mild skin rashes to severe anaphylaxis, a potentially life-threatening condition.

1.2 Pregnancy and breastfeeding: Baricitinib may harm an unborn baby and is not recommended during pregnancy. It is also advised to avoid the use of Baricitinib while breastfeeding, as it is unknown whether the drug passes into breast milk.

1.3 Active infections: Baricitinib affects the immune system and may increase the risk of infections. It is contraindicated in individuals with active infections, including tuberculosis, bacterial infections, fungal infections, and viral infections such as hepatitis B or C.

1.4 Live vaccines: The use of live vaccines is contraindicated in patients receiving Baricitinib. Baricitinib can weaken the immune system's response to vaccines, and live vaccines may cause severe infections in immunocompromised individuals.

2. Precautions and Warnings

While not absolute contraindications, the following precautions and warnings should be considered before using Baricitinib:

2.1 Thrombosis: Baricitinib may increase the risk of blood clots, including deep vein thrombosis (DVT) and pulmonary embolism. Individuals with a history of clotting disorders or those at an increased risk should be closely monitored while taking this medication.

2.2 Malignancy: The risk of malignancies may be increased with Baricitinib use. Patients with a history of cancer or those at high risk for developing malignancies should discuss the potential benefits and risks with their healthcare provider before starting Baricitinib treatment.

2.3 Laboratory abnormalities: Baricitinib can cause changes in laboratory values, such as changes in liver enzymes, cholesterol levels, and decreased hemoglobin levels. Regular monitoring of these values is recommended to ensure early detection of any abnormalities.

2.4 Renal and hepatic impairment: Patients with severe renal or hepatic impairment should use Baricitinib with caution, as the drug's safety and efficacy in these populations have not been adequately studied.

3. Conclusion

Baricitinib (Olumiant) is a valuable medication for the treatment of rheumatoid arthritis, COVID-19, and alopecia areata. However, it is important to be aware of the contraindications and precautions associated with its use. Patients should discuss their medical history and any current medical conditions with their healthcare provider before initiating Baricitinib treatment. Only by following the proper guidelines and considering individual factors can we ensure safe and effective use of this medication.